Psychedelic Drug Treatments
March 8, 2016 Ben Sessa, Eileen Worthley 1 citation
This book makes a case for re-evaluating psychedelic drugs—LSD, MDMA, DMT, psilocybin, ayahuasca, peyote, ibogaine, and more—as tools to assist clinical therapy. It covers how these chemical compounds affect the brain, defines key neurological and psychological terms, and describes disorders that may be helped, including post-traumatic stress disorder, depression, autism, and cluster headaches. The text discusses the history of mid-20th-century research halted by 1970s drug bans and examines the likelihood of a resurgence in developing psychedelic-assisted therapies. It aims to challenge 40-year-old prejudices against research into possible benefits of these drugs.